TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03177681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue Assessment
Description: The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tongue Assessment
Description: The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool Sample
Description: Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool Sample
Description: Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter Monitor
Description: Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter Monitor
Description: Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
Study: NCT05505370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Patients who meet all eligibility criteria were included and had a clinically indicated colonoscopy procedure performed using the study device. Immediately thereafter, patients had a colonoscopy procedure using standard colonoscope (Olympus CF 180) by a second endoscopist.
Study: NCT06102226

Intervention type: DIAGNOSTIC_TEST
Intervention: coronary artery imaging (coronary CTA or coronary angiography)
Description: In order to obtain the gold standard labeling for coronary heart disease, this topic will form a panel of experts on labeling, and the diagnosis will be based on coronary angiography, defined as a lesion with a stenosis of at least 50% in at least one coronary artery
Study: NCT05082181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPLIFT (Using Practice and Learning to Increase Favorable Thoughts)
Description: UPLIFT is an 8-week program that combines cognitive behavioral therapy (CBT) and mindfulness techniques and is delivered to small groups of participants by phone. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home practice assignment. CBT-related skills include thought monitoring, identifying cognitive distortions, problem identification, goal setting, and identifying supports. Relaxation exercises are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to breath, sights and sounds and other meditations. Audio guides are provided for home practice of mindfulness exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BOOST (Bringing Out Our Strength Together)
Description: BOOST is a telephone-based support program delivered in 8 weekly group sessions. Each weekly session is 1 hour long and is comprised of a check-in period, introduction of the week's topic, and group discussion. Weekly BOOST session topics include: (1) personal experience of epilepsy; (2) personal experience of mood problems (depression, anxiety, stress); (3) seizure triggers; (4) concerns related to epilepsy treatment (e.g., medication adherence, side effects); (5) changes in seizures over time; (6) the impact of behavior (e.g., sleep, substance use) on seizures; (7) social relationships and epilepsy; and (8) review of the BOOST experience.
Study: NCT06192030

Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict patient survival and gene signatures in ovarian metastases of colorectal cancer.

Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict patient survival and gene signatures in ovarian metastases of colorectal cancer.
Study: NCT05318235

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05675319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cells
Description: Allogeneic Stem Cell Transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carfilzomib/lenalidomide/dexamethasone (KRD)
Description: triple regimen for first relapse should be applied according to latest Summary of Product Characteristics (SmPC) version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elotuzumab/lenalidomide/dexamethasone (ERD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daratumumab/bortezomib/dexamethasone (DVD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daratumumab/lenalidomide/dexamethasone (DRD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ixazomib/lenalidomide/dexamethasone (IRD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pomalidomide/bortezomib/dexamethasone (PVD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carfilzomib/daratumumab/dexamethasone (KDD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cells
Description: Autologous Stem Cell Transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daratumumab/pomalidomide/dexamethasone (DPD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isatuximab/carfilzomib/dexamethasone (Isa-KD)
Description: triple regimen for first relapse should be applied according to latest SmPC version

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selinexor/bortezomib/dexamethasone (SVD)
Description: triple regimen for first relapse should be applied according to latest SmPC version
Study: NCT05428111

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: flow cytometric immunophynotyping
Description: Expression of programmed death-1 (PD-1) \& programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: flow cytometric immunophynotyping
Description: Expression of programmed death-1 (PD-1) \& programmed death ligand-1 (PDL-1) in flow cytometric immunophynotyping
Study: NCT05780762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPACT Program
Description: care at 3 levels:~(1) co-definition of the health situation, (2) co-planning of care and co-actions, and (3) co-assessment with the patient and with the team caring for him or her, and incorporating evidence-based measurement tools.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usal care
Description: usual management with a Nurse in Advanced Practice.
Study: NCT05450536

Intervention type: OTHER
Group type: OTHER
Intervention: Video Model and Role Play
Description: Video clips and role-play will be utilized to teach self-advocacy skills to autistic college students.
Study: NCT05574868

Intervention type: DEVICE
Group type: OTHER
Intervention: Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis
Description: Treatment: Erectile dysfunction
Study: NCT01165606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Study: NCT05480462

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clodivac
Description: A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td-Impfstoff Merieux
Description: One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.
Study: NCT05414383

Intervention type: DEVICE
Intervention: CADx
Description: A novel CADx system for real-time histopathological prediction of colorectal neoplasia, by using non-magnified conventional white-light and image enhanced endoscopy.
Study: NCT05715424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six interventions for children and adolescents
Description: * Vision Health Record Establishment and Myopia Risk Assessment.~* Evaluation of vision care behavior and development of reasonable eye use behavior.~* Health education for teachers and parents.~* Action to improve the reading and writing environment at home and school.~* One hour of outdoor activities in and out of school during the day.~* Myopia grading management and medical correction action.
Study: NCT05915533

Intervention type: OTHER
Group type: OTHER
Intervention: Dance therapy
Description: Before/after study to measure the effects of the dance therapy activity on the quality of life of the disabled adults housed in the establishments of UNIVI group.
Study: NCT05359692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: INCAGN1876 will be adminstered via IV at at the protocol-defined dose and schedule according to cohort and treatment group enrollment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV Q4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV Q4W
Study: NCT05834478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Cervical Vagal Nerve Stimulation
Description: Participants will receive stimulation of the vagus nerve with the non-invasive transcutaneous cervical Vagal Nerve Stimulation (tcVNS), which does not require surgery or implantation, and electrically stimulates the vagus nerve as it passes through the neck, dampening the sympathetic nervous system and modulating brain regions to a single side of the neck with the GammaCore device. Participants will be trained on self-stimulation and from days 1-7 patients undergo four times daily self-stimulation with tcVNS first for two minutes on one side, followed by a one-minute pause, then two minutes on the same side. The intensity of the stimulus (i.e. the current amplitude) will be adjusted by the user, to the maximum tolerable level without causing excessive pain \[typically 10-30 V and 60milliamperes (mA) (peak)\], with an alternating current (AC) signal consisting of five 5 kilohertz (kHz) pulses 200 microseconds in duration, repeating at a rate of 25 Hz (about once every 40 milliseconds).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Participants will have the same procedures as with the tcVNS but will instead receive a device that appears identical to the active tcVNS device in look, weight, visual and audible feedback, and also in user controls. The Sham device looks and sounds like an active device but does not deliver an electric current.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: [F-18]Fallypride
Description: \[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]Fallypride
Description: \[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
Study: NCT05359692

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV Q4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered via IV Q4W
Study: NCT05483465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Oral NR, 1g/day per os for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical pill to NR, daily per os for 8 weeks
Study: NCT05943184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Nursing Model
Description: (1)Psychological intervention was accessible to those who felt resistant to their treatment plans or developed inferior feelings due to visual impairment to establish a good relationship with patients and help them better cope with unhealthy emotions. (2) Health education was provided through self-developed booklets and question-and-answer sessions to publicize the fundamental knowledge and make sure all patients have a full understanding of the disease and related treatments. (3) Dietary guidelines were set out to encourage a light, healthy diet with fruits and vegetables, free of irritating food, and containing a limited amount of oily food. (4) Behavioral guidelines were developed to address the importance of quitting tobacco use and prevent eye strain due to excessive eye use with tailored eye care plans.
Study: NCT04421339

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Participants will receive melatonin 5 mg once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo once a day (30 min prior to bedtime) for four weeks, followed by one-week washout before crossing-over.
Study: NCT05950100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Description: It is composed of the physiotherapeutic procedures usually used in the hospital applied by the institution's physiotherapist, and the immersive virtual reality therapy that will be conducted by a third researcher (blind to the sampling and evaluations). Physiotherapeutic consultations will have the conventional duration offered by the Institution and therapy with virtual reality will last 10 minutes, using the game Aviãozinho. Both interventions will have a frequency of 2x a day (morning and afternoon shifts), during the period of 4 days.
Study: NCT05513183

Intervention type: PROCEDURE
Intervention: Intraoperative blood and peritoneal fluid samplings during HIPEC
Description: - Intraoperative samplings of blood and peritoneal fluids during HIPEC :~* Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~* Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)

Intervention type: PROCEDURE
Intervention: Intraoperative blood and peritoneal fluid samplings during HIPEC
Description: - Intraoperative samplings of blood and peritoneal fluids during HIPEC :~* Blood sampling of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90, 120 min)~* Peritoneal fluid sampline of 5ml at each time point (baseline, 0 (HIPEC starting point), 15, 30, 45, 60, 75, 90 min)
Study: NCT04188756

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: High intensity interval training (rehabilitation) over 15 weeks. Patients will be guided by physicians for exercise training in Pulmonary hypertension
Study: NCT05442346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γ-globin reactivated autologous hematopoietic stem cells
Description: gene edited autologous hematopoietic stem cells with γ-globin expression; BRL-103
Study: NCT06420050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instagram Intervention
Description: The intervention consists of a study Instagram page, which will post intervention content every day for 42 days.
Study: NCT05790525

Intervention type: DRUG
Group type: OTHER
Intervention: Standard bismuth quadruple
Description: Use the standard bismuth quadruple regimen recommended by the latest Chinese guidelines
Study: NCT05175950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose
Study: NCT05175950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03
Description: SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, 1 dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study: NCT06468163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug infusion into joint through catheter.
Description: With or without using catheter after DAIR operation for drug infusion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug infusion into joint through catheter.
Description: With or without using catheter after DAIR operation for drug infusion.
Study: NCT04852211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open or laparoscopic surgery
Description: Patients, with their consent, will be recruited to participate by investigators after considering the inclusion and exclusion criteria. Treatment allocation to the eligible patients will follow a randomization schedule. A total of 212 subjects will be randomized 1:1 to one of the two treatment arms:~1. Laparoscopic group: LMH~2. Open group: OMH
Study: NCT05820113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep learning based reconstruction of T2-TSE sequence
Description: A newly developed deep-learning based reconstruction of a primarily low-resolved T2-TSE sequence is included in the imaging protocol for evaluation of prostate cancer.